Creabilis SA
Treating inflammatory skin disorders by blocking a molecular pathway
This article was originally published in Start Up
Executive Summary
Nearly a decade ago, scientists began publishing studies that aroused excitement in the generally sleepy, low-innovation market for dermatology products. The finding that nerve growth factor is involved in inflammatory and autocrine diseases like psoriasis has since spurred many attempts to develop new treatments for underserved mild to moderate skin disorders. Several companies have taken into clinical-phase testing drug candidates that target different points along NGF’s pathway. For its part, Creabilis SA is developing a new chemical entity it believes can treat both psoriasis and atopic dermatitis by blocking NGF’s high affinity receptor, TrkA, with a kinase inhibitor presently known as CT327.